依达拉奉右莰醇治疗急性脑梗死的疗效与安全性  

Efficacy and safety of edaravone and dexborneol in treatment of acute cerebral infarction

作　　者：汪剑英 汤永红 WANG Jian-ying;TANG Yong-hong(Department of Neurology,Affiliated Nanhua Hospital,Hengyang Medical School,University of South China,Hengyang HU-NAN 421001,China;Department of Neurology,the Third Affiliated Hospital,Hengyang Medical School,University of South China,Hengyang HU-NAN 421900,China)

机构地区：[1]南华大学衡阳医学院附属南华医院神经内科,湖南衡阳421001 [2]南华大学衡阳医学院附属第三医院神经内科,湖南衡阳421900

出　　处：《中国新药与临床杂志》2024年第1期40-44,共5页Chinese Journal of New Drugs and Clinical Remedies

基　　金：湖南省科技创新重大项目(2020SK1012)。

摘　　要：目的观察依达拉奉右莰醇治疗急性脑梗死的疗效与安全性。方法选择急性脑梗死静脉溶栓患者120例,给予阿替普酶0.9 mg·kg^(-1)溶栓治疗,均分为对照组和研究组,研究组在溶栓完毕后给予依达拉奉右莰醇注射液37.5 mg静脉滴注,每12 h一次,疗程≤14 d。观察2组患者基线资料、溶栓前和溶栓后30 min、24 h和7 d的美国国立卫生研究院卒中量表(NIHSS)评分以及溶栓前和溶栓后24 h、7 d的改良Rankin量表(m RS)评分、溶栓前和溶栓后7 d超敏C反应蛋白(hs-CRP)与白细胞介素-6(IL-6)水平以及不良事件发生情况。结果溶栓后30 min,2组NIHSS评分均较溶栓前显著降低(P<0.05),组间比较无显著差异(P>0.05)。溶栓后24 h和7 d,2组NIHSS和m RS评分显著低于溶栓前,且研究组低于对照组(P<0.05)。研究组和对照组总有效率分别为80%和63%,组间比较差异显著(P<0.05)。溶栓后7 d,2组hs-CRP和IL-6水平显著低于溶栓前(P<0.05),研究组显著低于对照组(P<0.05)。治疗过程中研究组和对照组不良反应发生率分别为20%和22%,组间比较无显著差异(P>0.05)。结论依达拉奉右莰醇联合阿替普酶治疗急性脑梗死的临床疗效优于单用阿替普酶,且不增加溶栓治疗风险。AIM To investigate the efficacy and safety of edaravone and dexborneol in the treatment of acute cerebral infarction.METHODS A total of 120 patients with acute cerebral infarction for intravenous thrombolysis were selected,and were treated with alteplase 0.9 mg·kg^(-1) for thrombolysis.Then they were divided into control group and study group(n=60 in each group).The study group received intravenous infusion of 37.5 mg of edaravone and dexborneol injection after thrombolysis,once every 12 hours,for a course of≤14 days.The baseline data,National Institutes of Health Stroke Scale(NIHSS)scores before and after thrombolysis at 30 minutes,24 hours and 7 days,modified Rankin Scale(mRS)scores before and after thrombolysis at 24 hours and 7 days,the levels of hypersensitive C-reactive protein(hsCRP)and interleukin-6(IL-6)before and after thrombolysis at 7 days,and the occurrence of adverse events were observed.RESULTS After 30 minutes of thrombolysis,the NIHSS scores of the two groups were significantly reduced compared with before thrombolysis(P<0.05),and there was no significant difference between the groups(P>0.05).At 24 hours and 7 days after thrombolysis,the NIHSS and mRS scores of the two groups were significantly lower than before thrombolysis,and the study group was lower than the control group(P<0.05).The total effective rates of the study group and the control group were 80%and 63%,respectively,with significant differences between the two groups(P<0.05).At 7 days after thrombolysis,the levels of hsCRP and IL-6 in the two groups were significantly lower than those before thrombolysis(P<0.05),while the study group was significantly lower than the control group(P<0.05).During the thrombolysis process,the adverse reactions in the study group and control group were 20%and 22%,respectively,with no significant difference between the two groups(P>0.05).CONCLUSION The clinical efficacy of edaravone and dexborneol combined with alteplase in the treatment of acute cerebral infarction is better than that of alteplase alo

关 键 词：阿替普酶 依达拉奉右莰醇 脑梗死 C反应蛋白质 纤维蛋白溶解药 

分 类 号：R971[医药卫生—药品]